Hepatitis C viral load, genotype, and increased risk of developing end‐stage renal disease: REVEAL‐HCV study

Tai‐Shuan Lai, Mei‐Hsuan Lee, Hwai‐I Yang, San‐Lin You, Sheng‐Nan Lu, Li‐Yu Wang, Yong Yuan, Gilbert L'Italien, Kuo‐Liong Chien, Chien‐Jen Chen, for the REVEAL‐HCV Study Group – 2 April 2017 – The association between hepatitis C virus (HCV) infection and end‐stage renal disease (ESRD) remains controversial without considering the role of HCV viral load and genotype. This study aimed to determine whether HCV RNA level and genotype affect the risk of developing ESRD.

REPLY:

Constantine J. Karvellas, Jaime L. Speiser, Mélanie Tremblay, William M. Lee, Christopher F. Rose, For the US Acute Liver Failure Study Group – 2 April 2017

Allogeneic bone marrow–derived mesenchymal stromal cells for hepatitis B virus–related acute‐on‐chronic liver failure: A randomized controlled trial

Bing‐liang Lin, Jun‐feng Chen, Wei‐hong Qiu, Ke‐wei Wang, Dong‐ying Xie, Xiao‐yong Chen, Qiu‐li Liu, Liang Peng, Jian‐guo Li, Yong‐yu Mei, Wei‐zhen Weng, Yan‐wen Peng, Hui‐juan Cao, Jun‐qiang Xie, Shi‐bin Xie, Andy Peng Xiang, Zhi‐liang Gao – 1 April 2017 – Mortality from hepatitis B virus (HBV)–related acute‐on‐chronic liver failure (ACLF) is high due to limited treatment options. Preclinical and clinical investigations have proved that treatment with mesenchymal stromal cells (MSCs) is beneficial for recovery from liver injury.

Crosstalk of LKB1‐regulated and PTEN‐regulated signals in liver morphogenesis and tumor development in mice

Chengyou Jia, Vivian Medina, Chenchang Liu, Lina He, Daohai Qian, Taojian Tu, Curtis T. Okamoto, Bangyan L. Stiles – 1 April 2017 – Liver kinase B 1 (LKB1 or STK11) and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) are two tumor suppressors that regulate the mammalian target of rapamycin signaling pathway. Deletion studies show that loss of either Lkb1 (Lkb+/–) or Pten (PtenloxP/loxP; Alb‐Cre+) leads to liver injury and development of hepatocarcinoma. In this study, we investigated the crosstalk of LKB1 and PTEN loss during tumorigenesis and liver development.

Assessment of biopsy‐proven liver fibrosis by two‐dimensional shear wave elastography: An individual patient data‐based meta‐analysis

Eva Herrmann, Victor de Lédinghen, Christophe Cassinotto, Winnie C.‐W. Chu, Vivian Y.‐F. Leung, Giovanna Ferraioli, Carlo Filice, Laurent Castera, Valérie Vilgrain, Maxime Ronot, Jérôme Dumortier, Aymeric Guibal, Stanislas Pol, Jonel Trebicka, Christian Jansen, Christian Strassburg, Rongqin Zheng, Jian Zheng, Sven Francque, Thomas Vanwolleghem, Luisa Vonghia, Emanuel K.

Long‐term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years

James Fung, Tiffany Wong, Kenneth Chok, Albert Chan, Tan‐To Cheung, Jeff Wing‐Chiu Dai, Sui‐ling Sin, Ka‐Wing Ma, Kelvin Ng, Kevin Tak‐Pan Ng, Wai‐Kay Seto, Ching‐Lung Lai, Man‐Fung Yuen, Chung‐Mau Lo – 31 March 2017 – Long‐term antiviral prophylaxis is required to prevent hepatitis B recurrence for patients with chronic hepatitis B after liver transplantation. We determined the long‐term outcome of 265 consecutive chronic hepatitis B liver transplant recipients treated with entecavir monotherapy without hepatitis B immune globulin.

Subscribe to